Acadia Pharmaceuticals (ACAD) Research & Development (2010 - 2026)

Acadia Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $76.9 million for Q1 2026.

• On a quarterly basis, Research & Development fell 1.78% year-over-year to $76.9 million in Q1 2026; TTM through Mar 2026 was $327.4 million, a 1.73% increase from a year earlier, with the FY2025 full-year figure at $328.8 million, up 8.43% from the prior year.
• Research & Development fell to $76.9 million in Q1 2026 per ACAD's latest filing, from $84.8 million in the prior quarter.
• Across five years, Research & Development topped out at $157.0 million in Q3 2023 and bottomed at $58.8 million in Q2 2023.
• The 5-year median for Research & Development is $76.9 million (2026), against an average of $83.7 million.
• Across the five-year window, Research & Development surged 126.17% in 2022 and slumped 57.57% in 2024, its largest moves.
• Year by year, Research & Development stood at $75.7 million in 2022, then slipped by 11.88% to $66.7 million in 2023, then jumped by 50.93% to $100.7 million in 2024, then retreated by 15.86% to $84.8 million in 2025, then slipped by 9.31% to $76.9 million in 2026.
• Per Business Quant, the three latest ACAD Research & Development figures stand at $76.9 million (Q1 2026), $84.8 million (Q4 2025), and $87.8 million (Q3 2025).